Follow
Kine Eide Kvitne
Kine Eide Kvitne
Postdoctoral Researcher
Verified email at farmasi.uio.no
Title
Cited by
Cited by
Year
Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus
TAS Halden, KE Kvitne, K Midtvedt, L Rajakumar, I Robertsen, J Brox, ...
Diabetes care 42 (6), 1067-1074, 2019
1582019
Short‐and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity–a non‐randomized three‐armed controlled trial
KE Kvitne, I Robertsen, E Skovlund, H Christensen, V Krogstad, C Wegler, ...
Clinical and Translational Science 15 (1), 221-233, 2022
142022
Short‐and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity
KE Kvitne, V Krogstad, C Wegler, LK Johnson, MK Kringen, MH Hovd, ...
British Journal of Clinical Pharmacology 88 (9), 4121-4133, 2022
112022
Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body …
K Eide Kvitne, K Hole, V Krogstad, BM Wollmann, C Wegler, LK Johnson, ...
European journal of clinical pharmacology 78 (8), 1289-1299, 2022
102022
Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity
KE Kvitne, A Åsberg, LK Johnson, C Wegler, JK Hertel, P Artursson, ...
Clinical and Translational Science 15 (11), 2685-2696, 2022
72022
Intraindividual variability in absolute bioavailability and clearance of midazolam in healthy individuals
KE Kvitne, OM Drevland, N Haugli, E Skadberg, HK Zaré, A Åsberg, ...
Clinical Pharmacokinetics 62 (7), 981-987, 2023
22023
Neither gastric bypass surgery nor diet-induced weight-loss affect OATP1B1 activity as measured by rosuvastatin oral clearance
M Hovd, I Robertsen, LK Johnson, V Krogstad, C Wegler, KE Kvitne, ...
Clinical Pharmacokinetics 62 (5), 725-735, 2023
12023
Response to:“Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time”
KE Kvitne, K Hole, E Molden, I Robertsen
European Journal of Clinical Pharmacology 78 (11), 1865-1866, 2022
12022
Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals
KE Kvitne, M Hovd, LK Johnson, C Wegler, C Karlsson, P Artursson, ...
Clinical Pharmacokinetics 63 (1), 109-120, 2024
2024
Pharmacokinetic variability in patients with obesity and healthy individuals–the role of cytochrome P450
KE Kvitne
2022
The system can't perform the operation now. Try again later.
Articles 1–10